CAeditome Logo

Home

Download

Statistics

Landscape

Help

Contact
Center for Computational Systems Medicine
Soverview

1. Gene summary of enriched editing regions

Soverview

2. Tumor-specific enriched editing regions

Comparison of enriched editing regions between tumor and normal.

Correlation of enriched editing regions with tumor stages.

Associations of enriched editing regions with cancer survival.

Soverview

3. Enriched editing regions and immune related genes

Soverview

4. Enriched editing regions and immune related splicing

Soverview

5. Enriched editing regions and immune infiltration

Soverview

6. Enriched editing regions and immune gene sets

Correlation of enriched editing regions with epithelial-mesenchymal transition.

Correlations of enriched editing regions with hypoxic.

Associations of enriched editing regions with hallmark gene sets from MSigDB.

Soverview

7. Enriched editing regions and drugs

Correlations between enriched editing regions and drug sensitivity.

Enriched editing regions targeted by drugs from DrugBank database.

Editing gene: PHACTR4 (ImmuneEditome ID:65979)

1. Gene summary of enriched editing regions for PHACTR4

check button Gene summary
Gene informationGene symbol

PHACTR4

Gene ID

65979

GeneSynonymsPPP1R124
GeneCytomap

1p35.3

GeneTypeprotein-coding
GeneDescriptionphosphatase and actin regulator 4|protein phosphatase 1, regulatory subunit 124
GeneModificationdate20230329
UniprotIDQ8IZ21;A0A0J9YY52;A0A0J9YWV8;A0A0J9YVR0
PubMed ID

check buttonUCSC image.
all structure

check buttonLocations of each EERs.
EERENSTENSGGeneNameRegionRepeatdsRNA structure
chr1:28375021-28375601:+ENST00000463428.4ENSG00000204138.11PHACTR4ncRNA_intronicAluJr,AluSz6,A-richchr1:28375021-28375601:+.alignment
chr1:28375021-28375601:+ENST00000493669.1ENSG00000204138.11PHACTR4ncRNA_intronicAluJr,AluSz6,A-richchr1:28375021-28375601:+.alignment
chr1:28387025-28388141:+ENST00000463428.4ENSG00000204138.11PHACTR4ncRNA_intronicAluSx,AluSc,AluJrchr1:28387025-28388141:+.alignment
chr1:28387025-28388141:+ENST00000493669.1ENSG00000204138.11PHACTR4ncRNA_intronicAluSx,AluSc,AluJrchr1:28387025-28388141:+.alignment
chr1:28407845-28408519:+ENST00000463428.4ENSG00000204138.11PHACTR4ncRNA_intronicAluSz6,AluSx1chr1:28407845-28408519:+.alignment
chr1:28407845-28408519:+ENST00000493669.1ENSG00000204138.11PHACTR4ncRNA_intronicAluSz6,AluSx1chr1:28407845-28408519:+.alignment
chr1:28414433-28415216:+ENST00000463428.4ENSG00000204138.11PHACTR4ncRNA_intronicAluJo,AluSx3,HAL1,(A)nchr1:28414433-28415216:+.alignment
chr1:28414433-28415216:+ENST00000493669.1ENSG00000204138.11PHACTR4ncRNA_intronicAluJo,AluSx3,HAL1,(A)nchr1:28414433-28415216:+.alignment
chr1:28418321-28418739:+ENST00000463428.4ENSG00000204138.11PHACTR4ncRNA_intronicAluSx,AluSx1,L1ME4achr1:28418321-28418739:+.alignment
chr1:28418321-28418739:+ENST00000493669.1ENSG00000204138.11PHACTR4ncRNA_intronicAluSx,AluSx1,L1ME4achr1:28418321-28418739:+.alignment
chr1:28432445-28432992:+ENST00000463428.4ENSG00000204138.11PHACTR4ncRNA_intronicAluJb,AluJr4chr1:28432445-28432992:+.alignment
chr1:28432445-28432992:+ENST00000493669.1ENSG00000204138.11PHACTR4ncRNA_intronicAluJb,AluJr4chr1:28432445-28432992:+.alignment
chr1:28448988-28449781:+ENST00000463428.4ENSG00000204138.11PHACTR4ncRNA_intronicAluSx1,FAM,(ACA)n,AluJr4chr1:28448988-28449781:+.alignment
chr1:28448988-28449781:+ENST00000493669.1ENSG00000204138.11PHACTR4ncRNA_intronicAluSx1,FAM,(ACA)n,AluJr4chr1:28448988-28449781:+.alignment
chr1:28450674-28452353:+ENST00000463428.4ENSG00000204138.11PHACTR4ncRNA_intronicAluSz,Tigger2b_Pri,FAM,AluJr,AluJochr1:28450674-28452353:+.alignment
chr1:28450674-28452353:+ENST00000493669.1ENSG00000204138.11PHACTR4ncRNA_intronicAluSz,Tigger2b_Pri,FAM,AluJr,AluJochr1:28450674-28452353:+.alignment
chr1:28471908-28473269:+ENST00000493669.1ENSG00000204138.11PHACTR4ncRNA_intronicAluY,AluSx1,AluSz,MIRcchr1:28471908-28473269:+.alignment
chr1:28477741-28478906:+ENST00000493669.1ENSG00000204138.11PHACTR4ncRNA_intronic(TTTTTG)n,L1MA4,AluJo,AluJb,AluScchr1:28477741-28478906:+.alignment
chr1:28483186-28484282:+ENST00000493669.1ENSG00000204138.11PHACTR4ncRNA_intronicAluY,AluJr4,AluJb,MER58D,AluSxchr1:28483186-28484282:+.alignment
chr1:28486602-28488425:+ENST00000493669.1ENSG00000204138.11PHACTR4ncRNA_intronicAluJb,AluSx,AluSz,AluSc8,AluYchr1:28486602-28488425:+.alignment
chr1:28497343-28499801:+ENST00000373836.3ENSG00000204138.11PHACTR4UTR3AluSg,MER51B,AluJb,AluSx3,AluSx1,AluSp,(A)nchr1:28497343-28499801:+.alignment
chr1:28497343-28499801:+ENST00000373839.6ENSG00000204138.11PHACTR4UTR3AluSg,MER51B,AluJb,AluSx3,AluSx1,AluSp,(A)nchr1:28497343-28499801:+.alignment


Top

2. Tumor-specific enriched editing regions for PHACTR4


all structure

check buttonComparison of enriched editing regions between tumor and normal.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypePBoxplot
chr1:28497343-28499801:+BRCAEER9.4198e-03image
ENSG00000204138.11,PHACTR4BRCAEAG7.9615e-03image
chr1:28497343-28499801:+COADEER1.0879e-15image
ENSG00000204138.11,PHACTR4COADEAG2.1751e-16image
chr1:28497343-28499801:+HNSCEER1.9309e-14image
ENSG00000204138.11,PHACTR4HNSCEAG1.3258e-14image
chr1:28497343-28499801:+KIRCEER5.2696e-03image
ENSG00000204138.11,PHACTR4KIRCEAG3.8772e-03image
chr1:28497343-28499801:+THCAEER8.6125e-13image
ENSG00000204138.11,PHACTR4THCAEAG7.7839e-13image


Top

check buttonCorrelation of enriched editing regions with tumor stages.
* AnovaP<0.05, Pearson P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes, Path: Pathological stage, Cli: Clinical stage.
* Only shows the most significant correlation result of EERs/EAGs with either pathological stage or clinical stage according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeStageTypeAnovaPPRBoxplot
ENSG00000204138.11,PHACTR4BLCAPathEAG1.1998e-041.1198e-020.1256image
chr1:28497343-28499801:+BLCAPathEER2.8720e-046.6739e-030.1343image
ENSG00000204138.11,PHACTR4CESCCliEAG7.2360e-036.9003e-04-0.1952image
chr1:28497343-28499801:+CESCCliEER7.3155e-037.0376e-04-0.1949image
chr1:28497343-28499801:+THCAPathEER1.0753e-021.9490e-020.1042image
ENSG00000204138.11,PHACTR4THCAPathEAG9.8907e-031.5832e-020.1076image


Top

check button Associations of enriched editing regions with cancer survival.
* Pkm<0.05 and Pcox<0.05.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypeIDPkmPcox_continuousHR_continuousKMPlot
ENSG00000204138.11,PHACTR4ESCAEAG9.4887e-033.8458e-028.5294e-07image
chr1:28471908-28473269:+STADEER1.9856e-022.1520e-025.6432e+01image
chr1:28497343-28499801:+UCSEER3.6762e-031.4691e-023.5700e+10image
ENSG00000204138.11,PHACTR4UCSEAG3.6762e-031.4815e-023.4937e+10image

Top

3. Enriched editing regions and immune related genes for PHACTR4


all structure

check button Enriched editing regions and immune related genes.
* First, the associations between enriched editing regions and genes were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the gene relationships with immune were tested by three analyses: whether the gene is an immune gene (InnateDB、Immport、Immunome、Immunogenetic Related Information Source (IRIS)), whether the gene is associated with immune infiltration and whether the gene is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of genes with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeGenebetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark
chr1:28497343-28499801:+COADEERENSG00000201413,RNA5SP1410.11107.9694e-031.0054e-180.4998imageNNNADendritic_cells_activatedGSVA_HALLMARK_ESTROGEN_RESPONSE_LATE
chr1:28497343-28499801:+COADEERENSG00000223001,RNU2-61P0.10311.5820e-023.3176e-120.4044imageNNNADendritic_cells_activatedGSVA_HALLMARK_ESTROGEN_RESPONSE_LATE
chr1:28497343-28499801:+COADEERENSG00000200665,RNU6-1188P0.09792.2882e-027.8830e-220.5366imageNNNANeutrophilsGSVA_HALLMARK_UV_RESPONSE_UP
chr1:28497343-28499801:+COADEERENSG00000201031,Y_RNA0.08332.5499e-025.1569e-200.5156imageNNNADendritic_cells_activatedGSVA_HALLMARK_ESTROGEN_RESPONSE_LATE
chr1:28497343-28499801:+COADEERENSG00000252521,RNU5D-2P0.07743.2008e-021.0297e-260.5865imageNNNADendritic_cells_activatedGSVA_HALLMARK_ESTROGEN_RESPONSE_LATE
chr1:28497343-28499801:+COADEERENSG00000277918,U10.11113.9316e-022.8836e-230.5522imageNNNAMast_cells_activatedGSVA_HALLMARK_ESTROGEN_RESPONSE_LATE
chr1:28497343-28499801:+COADEERENSG00000268836,LA16c-OS12.2-0.18334.2781e-023.2813e-250.5720imageNELAVL1;HNRNPC;NOP56;NOP58NADendritic_cells_activatedGSVA_HALLMARK_PROTEIN_SECRETION
chr1:28497343-28499801:+COADEERENSG00000228499,TMSB10P10.17934.8705e-027.5930e-300.6145imageNNNAMast_cells_activatedGSVA_HALLMARK_HEME_METABOLISM
chr1:28497343-28499801:+DLBCEERENSG00000180787,ZFP3-0.75773.3309e-035.6502e-05-0.5578imageNELAVL1;NOP58NAB_cells_naiveGSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATION
chr1:28497343-28499801:+DLBCEERENSG00000106459,NRF1-0.75454.9382e-033.8723e-05-0.5677imageNELAVL1;FBL;HNRNPC;NOP56;NOP58NAT_cells_CD4_memory_restingGSVA_HALLMARK_XENOBIOTIC_METABOLISM
chr1:28497343-28499801:+COADEERENSG00000201413,RNA5SP1410.11107.9694e-031.0054e-180.4998imageNNNADendritic_cells_activatedGSVA_HALLMARK_ESTROGEN_RESPONSE_LATE
chr1:28497343-28499801:+COADEERENSG00000223001,RNU2-61P0.10311.5820e-023.3176e-120.4044imageNNNADendritic_cells_activatedGSVA_HALLMARK_ESTROGEN_RESPONSE_LATE
chr1:28497343-28499801:+COADEERENSG00000200665,RNU6-1188P0.09792.2882e-027.8830e-220.5366imageNNNANeutrophilsGSVA_HALLMARK_UV_RESPONSE_UP
chr1:28497343-28499801:+COADEERENSG00000201031,Y_RNA0.08332.5499e-025.1569e-200.5156imageNNNADendritic_cells_activatedGSVA_HALLMARK_ESTROGEN_RESPONSE_LATE
chr1:28497343-28499801:+COADEERENSG00000252521,RNU5D-2P0.07743.2008e-021.0297e-260.5865imageNNNADendritic_cells_activatedGSVA_HALLMARK_ESTROGEN_RESPONSE_LATE
chr1:28497343-28499801:+COADEERENSG00000277918,U10.11113.9316e-022.8836e-230.5522imageNNNAMast_cells_activatedGSVA_HALLMARK_ESTROGEN_RESPONSE_LATE
chr1:28497343-28499801:+COADEERENSG00000268836,LA16c-OS12.2-0.18334.2781e-023.2813e-250.5720imageNELAVL1;HNRNPC;NOP56;NOP58NADendritic_cells_activatedGSVA_HALLMARK_PROTEIN_SECRETION
chr1:28497343-28499801:+COADEERENSG00000228499,TMSB10P10.17934.8705e-027.5930e-300.6145imageNNNAMast_cells_activatedGSVA_HALLMARK_HEME_METABOLISM
chr1:28497343-28499801:+DLBCEERENSG00000180787,ZFP3-0.75773.3309e-035.6502e-05-0.5578imageNELAVL1;NOP58NAB_cells_naiveGSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATION
chr1:28497343-28499801:+DLBCEERENSG00000106459,NRF1-0.75454.9382e-033.8723e-05-0.5677imageNELAVL1;FBL;HNRNPC;NOP56;NOP58NAT_cells_CD4_memory_restingGSVA_HALLMARK_XENOBIOTIC_METABOLISM

More results



Top

4. Enriched editing regions and immune related splicing for PHACTR4


all structure

check button Enriched editing regions and immune related splicing.
* First, the associations between enriched editing regions and splicing events were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the splicing relationships with immune were tested by three analyses: whether the splicing event locates in an immune gene (InnateDB、Immport, Immunome and Immunogenetic Related Information Source (IRIS)), whether the splicing event is associated with immune infiltration and whether the splicing event is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of splicing events with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeSplicingTypeSplicingGeneSplicingChrSplicingPositionbetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark
chr1:28497343-28499801:+
COADEERIRENSG00000141569.6chr1775888959:75891878:75892010:75892149-0.22852.2812e-022.3800e-120.4183imageNELAVL1;FBL;HNRNPC;NOP56;NOP58TRIM65Dendritic_cells_activatedGSVA_HALLMARK_UV_RESPONSE_UP
ENSG00000204138.11,PHACTR4
COADEAGMEXENSG00000166340.10chr116617010:6617153:6617300:6617428:6618775:6618915:6619195:66192670.22394.1252e-023.0804e-170.4806imageNACIN1;ADAR;AIFM1;AUH;BCCIP;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;EIF4A3;EIF4G2;ELAVL1;ELAVL3;FAM120A;FBL;FMR1;FUS;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHSRP;LARP4B;LARP7;LIN28;LIN28A;LIN28B;LSM11;MBNL1;MBNL2;MOV10;MSI1;MSI2;NONO;NOP56;NOP58;NPM1;NUMA1;PCBP2;PRPF8;PTBP1;QKI;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RBM47;RBM5;RNF219;SAFB2;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YTHDC1;YTHDF1;YWHAG;ZNF184NADendritic_cells_activatedGSVA_HALLMARK_DNA_REPAIR
ENSG00000204138.11,PHACTR4
COADEAGIRENSG00000131051.16chr2035729311:35729362:35729461:357295270.23132.7026e-026.5101e-190.5030imageNACIN1;ADAR;AIFM1;ALKBH5;ALYREF;AUH;BCCIP;BUD13;CAPRIN1;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DICER1;DKC1;EIF4A3;EIF4G2;ELAVL1;ELAVL3;EWSR1;FAM120A;FBL;FKBP4;FMR1;FTO;FUS;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPD;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHDRBS3;KHSRP;LARP4B;LARP7;LIN28;LIN28A;LIN28B;LSM11;MBNL2;METTL3;MOV10;MSI1;MSI2;NCBP3;NONO;NOP56;NOP58;NPM1;NUMA1;PCBP2;PRPF8;PTBP1;PUM2;QKI;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RBM47;RBM5;RC3H1;RNF219;SAFB2;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARBP2;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;XRN2;YTHDC1;YTHDF1;YWHAG;ZC3H7B;ZFP36;ZNF184NAEosinophilsGSVA_HALLMARK_UV_RESPONSE_UP
ENSG00000204138.11,PHACTR4
COADEAGMEXENSG00000161800.8chr1250002271:50002300:50004234:50004266:50016630:50016719:50025397:500254380.21914.8088e-024.3949e-130.4213imageNACIN1;ADAR;ALKBH5;ALYREF;AUH;BUD13;CAPRIN1;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DICER1;DKC1;EIF4A3;EIF4G2;ELAVL1;EWSR1;FAM120A;FBL;FMR1;FTO;FUS;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPD;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHDRBS3;KHSRP;LARP4B;LIN28;LIN28A;LIN28B;LSM11;METTL3;MOV10;MSI1;MSI2;NCBP3;NONO;NOP56;NOP58;NPM1;NUMA1;PCBP2;PRPF8;PTBP1;PUM2;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RBM5;RC3H1;RNF219;SAFB2;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARBP2;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;XRN2;YTHDC1;YTHDF1;YWHAG;ZC3H7B;ZFP36;ZNF184RACGAP1EosinophilsGSVA_HALLMARK_UV_RESPONSE_UP
chr1:28497343-28499801:+
COADEERMEXENSG00000106397.7chr7101206778:101206904:101207577:101207664:101207664:101207724:101208852:1012089570.23592.3026e-022.9180e-360.6662imageNELAVL1;FBL;HNRNPC;NOP56;NOP58NADendritic_cells_activatedGSVA_HALLMARK_ESTROGEN_RESPONSE_LATE
ENSG00000204138.11,PHACTR4
COADEAGA5ENSG00000060138.8chr1210704054:10704148:10713210:10713333:10709907:10713333-0.21844.8225e-021.0021e-13-0.4295imageNACIN1;ADAR;AIFM1;ALYREF;AUH;BCCIP;BUD13;CAPRIN1;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DKC1;EIF4A3;EIF4G2;ELAVL1;ELAVL3;EWSR1;FAM120A;FBL;FKBP4;FMR1;FTO;FUS;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPD;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHDRBS3;KHSRP;LARP4B;LARP7;LIN28;LIN28A;LIN28B;LSM11;MOV10;MSI2;NONO;NOP56;NOP58;NPM1;NUMA1;PCBP2;PRPF8;PTBP1;QKI;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RBM47;RBM5;RNF219;SAFB2;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;XRN2;YTHDC1;YWHAG;ZC3H7B;ZNF184NAEosinophilsGSVA_HALLMARK_FATTY_ACID_METABOLISM
ENSG00000204138.11,PHACTR4
COADEAGIRENSG00000068878.10chr253936086:53936161:53936763:539368270.18293.4258e-027.0381e-180.5152imageNACIN1;ADAR;AIFM1;ALYREF;AUH;BCCIP;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DICER1;DKC1;EIF4A3;EIF4G2;ELAVL1;ELAVL3;EWSR1;FAM120A;FBL;FKBP4;FMR1;FTO;FUS;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPD;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHDRBS3;KHSRP;LARP7;LIN28;LIN28A;LIN28B;LSM11;MBNL2;METTL3;MOV10;MSI1;MSI2;NONO;NOP56;NOP58;NPM1;NUMA1;PCBP2;PRPF8;PTBP1;PUM2;QKI;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RBM47;RBM5;RC3H1;RNF219;SAFB2;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARBP2;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;XRN2;YTHDC1;YTHDF1;YWHAG;ZC3H7B;ZNF184PSME4EosinophilsGSVA_HALLMARK_ESTROGEN_RESPONSE_LATE
ENSG00000204138.11,PHACTR4
COADEAGA5ENSG00000075413.13chr14103502881:103503066:103498501:103498528:103498501:1035002000.22282.7435e-021.2875e-110.4089imageNACIN1;ADAR;AIFM1;ALKBH5;ALYREF;AUH;BCCIP;BUD13;CAPRIN1;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DICER1;DKC1;EIF4A3;EIF4G2;ELAVL1;ELAVL3;EWSR1;FAM120A;FBL;FKBP4;FMR1;FTO;FUS;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPD;HNRNPK;HNRNPL;HNRNPM;HNRNPU;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHDRBS3;KHSRP;LARP4B;LARP7;LIN28;LIN28A;LIN28B;LSM11;MBNL2;MOV10;MSI1;MSI2;NCBP3;NONO;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;QKI;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RBM47;RBM5;SAFB2;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARBP2;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;XRN2;YTHDC1;YTHDF1;YWHAG;ZC3H7B;ZNF184MARK3NeutrophilsGSVA_HALLMARK_UV_RESPONSE_DN
ENSG00000204138.11,PHACTR4
COADEAGIRENSG00000173559.8chr2191682491:191683804:191684229:1916842780.20984.8462e-021.9856e-210.5379imageNACIN1;ADAR;ALYREF;AUH;BCCIP;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DKC1;EIF4A3;EIF4G2;ELAVL1;EWSR1;FAM120A;FBL;FKBP4;FMR1;FUS;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHSRP;LARP4B;LARP7;LIN28;LIN28B;LSM11;MOV10;NONO;NOP56;NOP58;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RBM47;RNF219;SAFB2;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YTHDC1;YTHDF1;YWHAG;ZC3H7B;ZNF184NAEosinophilsGSVA_HALLMARK_ESTROGEN_RESPONSE_LATE
ENSG00000204138.11,PHACTR4
COADEAGIRENSG00000182718.12chr1560394573:60396427:60397257:603973380.19954.8477e-021.2014e-250.6162imageNACIN1;ADAR;AIFM1;ALYREF;AUH;BCCIP;BUD13;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DKC1;EIF4A3;EIF4G2;ELAVL1;ELAVL3;EWSR1;FAM120A;FBL;FKBP4;FMR1;FUS;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHDRBS3;KHSRP;LARP4B;LARP7;LIN28;LIN28A;LIN28B;LSM11;MBNL1;MBNL2;MOV10;MSI1;MSI2;NONO;NOP56;NOP58;NPM1;NUMA1;PCBP2;PRPF8;PTBP1;QKI;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RBM47;RBM5;RNF219;SAFB2;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARBP2;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YTHDC1;YWHAG;ZNF184ANXA2EosinophilsGSVA_HALLMARK_UV_RESPONSE_UP

More results



Top

5. Enriched editing regions and immune infiltration for PHACTR4


all structure

check button Associations of enriched editing regions with immune infiltration.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the fraction of different immune cells according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeIDImmuneCellPRCorrelationPlot
chr1:28497343-28499801:+ACCEERMacrophages_M22.7586e-020.2511image
ENSG00000204138.11,PHACTR4ACCEAGMacrophages_M22.7586e-020.2511image
chr1:28497343-28499801:+BLCAEERMacrophages_M14.8719e-070.2466image
ENSG00000204138.11,PHACTR4BLCAEAGMacrophages_M12.7601e-070.2517image
chr1:28497343-28499801:+BRCAEERB_cells_naive1.1739e-03-0.0986image
ENSG00000204138.11,PHACTR4BRCAEAGB_cells_naive1.1093e-03-0.0990image
chr1:28497343-28499801:+CESCEERDendritic_cells_activated9.0927e-030.1494image
ENSG00000204138.11,PHACTR4CESCEAGDendritic_cells_activated5.6564e-030.1584image
chr1:28497343-28499801:+COADEERDendritic_cells_activated1.1070e-060.2893image
ENSG00000204138.11,PHACTR4COADEAGEosinophils8.9436e-090.3380image
chr1:28497343-28499801:+DLBCEERB_cells_naive2.4957e-03-0.4354image
ENSG00000204138.11,PHACTR4DLBCEAGB_cells_naive2.7041e-03-0.4322image
chr1:28497343-28499801:+ESCAEERDendritic_cells_resting2.1461e-03-0.2402image
ENSG00000204138.11,PHACTR4ESCAEAGDendritic_cells_resting2.0119e-03-0.2417image
chr1:28497343-28499801:+GBMEERMacrophages_M02.3390e-03-0.2340image
ENSG00000204138.11,PHACTR4GBMEAGMacrophages_M02.2629e-03-0.2347image
chr1:28497343-28499801:+HNSCEERNK_cells_resting1.4475e-050.1926image
ENSG00000204138.11,PHACTR4HNSCEAGNK_cells_resting2.9846e-050.1855image
chr1:28497343-28499801:+KICHEERB_cells_naive3.2488e-02-0.2656image
ENSG00000204138.11,PHACTR4KICHEAGB_cells_naive3.2488e-02-0.2656image
chr1:28497343-28499801:+KIRCEERDendritic_cells_resting2.4169e-03-0.1544image
ENSG00000204138.11,PHACTR4KIRCEAGDendritic_cells_resting6.9398e-03-0.1376image
chr1:28497343-28499801:+KIRPEERT_cells_CD4_memory_resting2.9591e-03-0.1751image
ENSG00000204138.11,PHACTR4KIRPEAGT_cells_CD4_memory_resting8.3945e-03-0.1553image
chr1:28497343-28499801:+LAMLEERMonocytes4.9542e-030.2346image
ENSG00000204138.11,PHACTR4LAMLEAGMonocytes7.7318e-030.2196image
chr1:28497343-28499801:+LGGEERT_cells_CD4_memory_activated1.2561e-030.1400image
ENSG00000204138.11,PHACTR4LGGEAGT_cells_CD4_memory_activated1.2552e-030.1400image
chr1:28497343-28499801:+LUADEEREosinophils3.2751e-090.2572image
ENSG00000204138.11,PHACTR4LUADEAGEosinophils1.3460e-050.1903image
chr1:28497343-28499801:+LUSCEERT_cells_CD4_memory_activated1.1269e-070.2352image
ENSG00000204138.11,PHACTR4LUSCEAGT_cells_CD4_memory_activated1.1541e-070.2350image
chr1:28497343-28499801:+MESOEERT_cells_CD89.1595e-030.2861image
ENSG00000204138.11,PHACTR4MESOEAGT_cells_CD89.1595e-030.2861image
chr1:28414433-28415216:+OVEERMacrophages_M02.0274e-020.3570image
chr1:28448988-28449781:+OVEEREosinophils1.2168e-020.3070image
chr1:28497343-28499801:+OVEERT_cells_CD83.7768e-020.1216image
ENSG00000204138.11,PHACTR4OVEAGT_cells_CD82.9158e-020.1277image
chr1:28497343-28499801:+PCPGEERT_cells_follicular_helper4.7690e-02-0.1486image
ENSG00000204138.11,PHACTR4PCPGEAGT_cells_follicular_helper4.7690e-02-0.1486image
chr1:28497343-28499801:+PRADEERPlasma_cells6.8913e-04-0.1514image
ENSG00000204138.11,PHACTR4PRADEAGPlasma_cells6.5749e-04-0.1520image
chr1:28497343-28499801:+READEERT_cells_CD4_memory_activated2.4876e-03-0.3069image
ENSG00000204138.11,PHACTR4READEAGT_cells_CD4_memory_activated2.3621e-03-0.3084image
chr1:28497343-28499801:+SARCEERB_cells_memory1.5330e-02-0.1511image
ENSG00000204138.11,PHACTR4SARCEAGB_cells_memory1.5327e-02-0.1511image
chr1:28497343-28499801:+SKCMEERT_cells_CD82.4970e-060.2150image
ENSG00000204138.11,PHACTR4SKCMEAGT_cells_CD81.6273e-060.2188image
chr1:28407845-28408519:+STADEERPlasma_cells2.0042e-020.2775image
chr1:28414433-28415216:+STADEERMacrophages_M11.0565e-030.2990image
chr1:28448988-28449781:+STADEERMonocytes2.5935e-030.4384image
chr1:28471908-28473269:+STADEERNK_cells_activated1.9314e-020.3299image
chr1:28483186-28484282:+STADEERMast_cells_resting3.1536e-020.3933image
chr1:28497343-28499801:+STADEERT_cells_CD4_memory_activated4.1935e-020.1057image
ENSG00000204138.11,PHACTR4STADEAGNK_cells_activated1.4233e-020.1272image
chr1:28497343-28499801:+TGCTEERMacrophages_M23.8183e-04-0.2818image
ENSG00000204138.11,PHACTR4TGCTEAGMacrophages_M23.8183e-04-0.2818image
chr1:28497343-28499801:+THCAEERT_cells_regulatory_(Tregs)3.7037e-040.1581image
ENSG00000204138.11,PHACTR4THCAEAGT_cells_regulatory_(Tregs)2.1771e-040.1642image
ENSG00000204138.11,PHACTR4THYMEAGNK_cells_resting3.6605e-020.1960image
chr1:28497343-28499801:+UCECEERDendritic_cells_resting3.9261e-02-0.1560image
chr1:28497343-28499801:+UCSEERB_cells_naive1.1200e-03-0.4242image
ENSG00000204138.11,PHACTR4UCSEAGB_cells_naive1.1134e-03-0.4244image
chr1:28497343-28499801:+UVMEERT_cells_CD4_naive3.3569e-030.3282image
ENSG00000204138.11,PHACTR4UVMEAGT_cells_CD4_naive3.3569e-030.3282image


Top

6. Enriched editing regions and immune gene sets for PHACTR4


all structure

check button Correlation of enriched editing regions with epithelial-mesenchymal transition.
* First, the differences of enriched editing regions between Epi and Mes groups (defined by KS-test) were compared (P<0.05 and Informative number >=20).
* Second, the correlations between enriched editing regions and gene set score of HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly edited between Epi and Mes group.
ID_eventscancerTypeE2M_PBoxplotCorPCorRCorrelationPlot
chr1:28497343-28499801:+BLCAEER2.0356e-02image2.0869e-100.3086image
ENSG00000204138.11,PHACTR4BLCAEAG1.8335e-02image1.5411e-110.3265image
chr1:28497343-28499801:+LUSCEER2.9606e-02image1.5000e-040.1693image
ENSG00000204138.11,PHACTR4LUSCEAG2.9844e-02image1.5343e-040.1690image


Top

check button Correlations of enriched editing regions with hypoxic.
* First, there are four hypoxia scores used in the database. The first three hypoxic scores were calculated on three gene sets of Buffa, Ragnum and Winter based on one previous study (PMID: 32024819). One last hypoxia score was defined on HALLMARK_HYPOXIA by GSVA method.
* Second, the correlations enriched editing regions with the four hypoxic scores were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly correlated with all four hypoxia gene set scores. For more results, please go to download page.
ID_eventscancerTypeBuffa_P Buffa_R Ragnum_P Ragnum_R Winter_P Winter_R HALLMARK_P HALLMARK_R CorrelationPlot
chr1:28497343-28499801:+BLCAEER2.9501e-030.14723.8918e-020.10251.2817e-020.12343.0945e-070.2507image
chr1:28497343-28499801:+LIHCEER3.7132e-03-0.15116.0161e-06-0.23389.5177e-04-0.17182.8941e-020.1140image


Top

check button Associations of enriched editing regions with hallmark gene sets from MSigDB.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerHallmarkTypeTypePRCorrelationPlot
chr1:28497343-28499801:+ACCGSVA_HALLMARK_DNA_REPAIREER1.9363e-03-0.3478image
ENSG00000204138.11,PHACTR4ACCGSVA_HALLMARK_DNA_REPAIREAG1.9363e-03-0.3478image
ENSG00000204138.11,PHACTR4BLCAGSVA_HALLMARK_COMPLEMENTEAG1.5606e-120.3413image
chr1:28497343-28499801:+BLCAGSVA_HALLMARK_INFLAMMATORY_RESPONSEEER2.9389e-110.3222image
ENSG00000204138.11,PHACTR4BRCAGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG3.7695e-110.1992image
chr1:28497343-28499801:+BRCAGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER2.5974e-130.2200image
chr1:28497343-28499801:+CESCGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSEEER2.9070e-060.2646image
ENSG00000204138.11,PHACTR4CESCGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG5.6389e-060.2570image
chr1:28497343-28499801:+CHOLGSVA_HALLMARK_NOTCH_SIGNALINGEER8.5747e-030.4376image
ENSG00000204138.11,PHACTR4CHOLGSVA_HALLMARK_NOTCH_SIGNALINGEAG8.5747e-030.4376image
chr1:28497343-28499801:+COADGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALINGEER5.3253e-04-0.2079image
ENSG00000204138.11,PHACTR4COADGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALINGEAG3.8589e-07-0.3004image
chr1:28497343-28499801:+DLBCGSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATIONEER1.8019e-030.4479image
ENSG00000204138.11,PHACTR4DLBCGSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATIONEAG1.6727e-030.4507image
chr1:28414433-28415216:+ESCAGSVA_HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITIONEER1.6848e-040.5668image
ENSG00000204138.11,PHACTR4ESCAGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSEEAG9.7457e-040.2575image
chr1:28497343-28499801:+ESCAGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSEEER2.9622e-040.2816image
chr1:28497343-28499801:+GBMGSVA_HALLMARK_XENOBIOTIC_METABOLISMEER2.3921e-060.3557image
ENSG00000204138.11,PHACTR4GBMGSVA_HALLMARK_XENOBIOTIC_METABOLISMEAG2.4838e-060.3552image
ENSG00000204138.11,PHACTR4HNSCGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG6.5707e-110.2866image
chr1:28497343-28499801:+HNSCGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER1.9089e-110.2943image
ENSG00000204138.11,PHACTR4KICHGSVA_HALLMARK_G2M_CHECKPOINTEAG2.3142e-03-0.3715image
chr1:28497343-28499801:+KICHGSVA_HALLMARK_G2M_CHECKPOINTEER2.3142e-03-0.3715image
chr1:28497343-28499801:+KIRCGSVA_HALLMARK_COAGULATIONEER4.6458e-040.1778image
ENSG00000204138.11,PHACTR4KIRCGSVA_HALLMARK_COMPLEMENTEAG2.8079e-020.1121image
chr1:28497343-28499801:+KIRPGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAYEER1.3138e-030.1891image
ENSG00000204138.11,PHACTR4KIRPGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAYEAG1.0954e-030.1918image
chr1:28450674-28452353:+LAMLGSVA_HALLMARK_MYC_TARGETS_V1EER2.2871e-03-0.4580image
ENSG00000204138.11,PHACTR4LAMLGSVA_HALLMARK_DNA_REPAIREAG9.3488e-05-0.3176image
chr1:28497343-28499801:+LAMLGSVA_HALLMARK_SPERMATOGENESISEER3.0359e-03-0.2471image
ENSG00000204138.11,PHACTR4LGGGSVA_HALLMARK_G2M_CHECKPOINTEAG7.5786e-13-0.3052image
chr1:28497343-28499801:+LGGGSVA_HALLMARK_BILE_ACID_METABOLISMEER6.4503e-130.3061image
ENSG00000204138.11,PHACTR4LIHCGSVA_HALLMARK_COAGULATIONEAG2.3380e-040.1907image
chr1:28497343-28499801:+LIHCGSVA_HALLMARK_COAGULATIONEER1.1393e-060.2508image
ENSG00000204138.11,PHACTR4LUADGSVA_HALLMARK_HYPOXIAEAG1.1838e-050.1915image
chr1:28497343-28499801:+LUADGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALINGEER3.8746e-04-0.1559image
chr1:28497343-28499801:+LUSCGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSEEER1.6137e-120.3098image
ENSG00000204138.11,PHACTR4LUSCGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSEEAG1.6727e-120.3096image
chr1:28497343-28499801:+MESOGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAYEER2.8290e-030.3257image
ENSG00000204138.11,PHACTR4MESOGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAYEAG2.8290e-030.3257image
chr1:28448988-28449781:+OVGSVA_HALLMARK_PANCREAS_BETA_CELLSEER3.3211e-020.2625image
chr1:28497343-28499801:+OVGSVA_HALLMARK_PEROXISOMEEER1.0510e-090.3474image
chr1:28414433-28415216:+OVGSVA_HALLMARK_DNA_REPAIREER2.6481e-030.4521image
ENSG00000204138.11,PHACTR4OVGSVA_HALLMARK_PEROXISOMEEAG2.0745e-080.3207image
ENSG00000204138.11,PHACTR4PAADGSVA_HALLMARK_MYOGENESISEAG4.8396e-020.1486image
chr1:28497343-28499801:+PAADGSVA_HALLMARK_MYOGENESISEER4.8396e-020.1486image
chr1:28497343-28499801:+PCPGGSVA_HALLMARK_SPERMATOGENESISEER1.4676e-020.1826image
ENSG00000204138.11,PHACTR4PCPGGSVA_HALLMARK_SPERMATOGENESISEAG1.4676e-020.1826image
ENSG00000204138.11,PHACTR4PRADGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAYEAG5.8913e-040.1533image
chr1:28497343-28499801:+PRADGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAYEER3.5790e-040.1592image
ENSG00000204138.11,PHACTR4READGSVA_HALLMARK_MYC_TARGETS_V2EAG7.6207e-04-0.3395image
chr1:28497343-28499801:+READGSVA_HALLMARK_MYC_TARGETS_V2EER7.0386e-04-0.3416image
ENSG00000204138.11,PHACTR4SARCGSVA_HALLMARK_APOPTOSISEAG4.3980e-030.1771image
chr1:28497343-28499801:+SARCGSVA_HALLMARK_APOPTOSISEER4.3145e-030.1775image
chr1:28497343-28499801:+SKCMGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER2.6943e-080.2527image
ENSG00000204138.11,PHACTR4SKCMGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG2.8054e-080.2524image
chr1:28448988-28449781:+STADGSVA_HALLMARK_COAGULATIONEER1.9594e-030.4493image
chr1:28471908-28473269:+STADGSVA_HALLMARK_APICAL_SURFACEEER7.3637e-030.3746image
chr1:28414433-28415216:+STADGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER8.1644e-030.2435image
ENSG00000204138.11,PHACTR4STADGSVA_HALLMARK_MITOTIC_SPINDLEEAG1.2744e-04-0.1976image
chr1:28483186-28484282:+STADGSVA_HALLMARK_KRAS_SIGNALING_DNEER3.0091e-020.3964image
chr1:28450674-28452353:+STADGSVA_HALLMARK_P53_PATHWAYEER1.8826e-030.6247image
ENSG00000204138.11,PHACTR4TGCTGSVA_HALLMARK_TGF_BETA_SIGNALINGEAG3.9778e-04-0.2810image
chr1:28497343-28499801:+TGCTGSVA_HALLMARK_TGF_BETA_SIGNALINGEER3.9778e-04-0.2810image
chr1:28497343-28499801:+THCAGSVA_HALLMARK_ESTROGEN_RESPONSE_LATEEER2.8457e-080.2443image
ENSG00000204138.11,PHACTR4THCAGSVA_HALLMARK_ESTROGEN_RESPONSE_LATEEAG2.2301e-080.2462image
ENSG00000204138.11,PHACTR4THYMGSVA_HALLMARK_KRAS_SIGNALING_DNEAG1.4821e-040.3480image
chr1:28497343-28499801:+THYMGSVA_HALLMARK_KRAS_SIGNALING_DNEER2.6869e-050.3840image
chr1:28497343-28499801:+UCECGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER1.9980e-030.2321image
ENSG00000204138.11,PHACTR4UCECGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG3.6468e-030.2180image
chr1:28497343-28499801:+UCSGSVA_HALLMARK_APOPTOSISEER3.8835e-030.3798image
ENSG00000204138.11,PHACTR4UCSGSVA_HALLMARK_APOPTOSISEAG3.9024e-030.3797image
chr1:28497343-28499801:+UVMGSVA_HALLMARK_CHOLESTEROL_HOMEOSTASISEER7.4893e-040.3738image
ENSG00000204138.11,PHACTR4UVMGSVA_HALLMARK_CHOLESTEROL_HOMEOSTASISEAG7.4893e-040.3738image


Top

7. Enriched editing regions and drugs for PHACTR4


all structure

check button Correlations between enriched editing regions and drug sensitivity.
* First, the drug sensitivity (IS50) was estimated on 84 drugs by pRRophetic package.
* Second, the correlations between editing enriched regions and drug sensitivity were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the IS50 scores of 84 drugs according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerDrugTypePRCorrelationPlot
chr1:28497343-28499801:+ACCIPA.3EER4.7145e-030.3188image
ENSG00000204138.11,PHACTR4ACCIPA.3EAG4.7145e-030.3188image
ENSG00000204138.11,PHACTR4BLCACMKEAG2.1391e-12-0.3393image
chr1:28497343-28499801:+BLCACMKEER3.8866e-10-0.3042image
chr1:28497343-28499801:+BRCACHIR.99021EER6.3178e-040.1038image
ENSG00000204138.11,PHACTR4BRCACHIR.99021EAG1.0486e-030.0995image
ENSG00000204138.11,PHACTR4CESCBMS.536924EAG5.9157e-05-0.2290image
chr1:28497343-28499801:+CESCBMS.536924EER2.3186e-04-0.2103image
ENSG00000204138.11,PHACTR4CHOLEmbelinEAG2.2457e-02-0.3848image
chr1:28497343-28499801:+CHOLEmbelinEER2.2457e-02-0.3848image
chr1:28497343-28499801:+COADBMS.708163EER8.5453e-05-0.2351image
ENSG00000204138.11,PHACTR4COADGW843682XEAG1.1210e-090.3568image
chr1:28497343-28499801:+DLBCA.770041EER1.0800e-05-0.5993image
ENSG00000204138.11,PHACTR4DLBCA.770041EAG1.2335e-05-0.5962image
chr1:28497343-28499801:+ESCABexaroteneEER5.5298e-04-0.2692image
chr1:28414433-28415216:+ESCAAZD6482EER4.8772e-05-0.6028image
ENSG00000204138.11,PHACTR4ESCACGP.60474EAG2.7824e-03-0.2342image
chr1:28497343-28499801:+GBMBIBW2992EER1.3019e-06-0.3643image
ENSG00000204138.11,PHACTR4GBMBIBW2992EAG1.2548e-06-0.3648image
ENSG00000204138.11,PHACTR4HNSCCI.1040EAG1.1884e-09-0.2677image
chr1:28497343-28499801:+HNSCCI.1040EER4.3727e-08-0.2418image
ENSG00000204138.11,PHACTR4KICHLenalidomideEAG9.9176e-03-0.3177image
chr1:28497343-28499801:+KICHLenalidomideEER9.9176e-03-0.3177image
ENSG00000204138.11,PHACTR4KIRCJNK.9LEAG1.8508e-030.1584image
chr1:28497343-28499801:+KIRCCI.1040EER3.4685e-04-0.1816image
chr1:28497343-28499801:+KIRPCCT018159EER2.5014e-050.2464image
ENSG00000204138.11,PHACTR4KIRPCCT018159EAG1.0989e-040.2263image
chr1:28450674-28452353:+LAMLDocetaxelEER9.4109e-030.3961image
ENSG00000204138.11,PHACTR4LAMLA.443654EAG2.4575e-040.2990image
chr1:28497343-28499801:+LAMLCI.1040EER1.3097e-03-0.2671image
ENSG00000204138.11,PHACTR4LGGGSK.650394EAG3.8173e-160.3444image
chr1:28497343-28499801:+LGGGSK.650394EER1.9847e-160.3475image
ENSG00000204138.11,PHACTR4LIHCCI.1040EAG1.4180e-05-0.2242image
chr1:28497343-28499801:+LIHCDMOGEER3.4318e-05-0.2145image
ENSG00000204138.11,PHACTR4LUADGemcitabineEAG1.3761e-06-0.2107image
chr1:28497343-28499801:+LUADGemcitabineEER1.7849e-06-0.2089image
chr1:28497343-28499801:+LUSCCI.1040EER9.7142e-10-0.2698image
ENSG00000204138.11,PHACTR4LUSCCI.1040EAG9.9208e-10-0.2697image
ENSG00000204138.11,PHACTR4MESOMG.132EAG1.6867e-04-0.4038image
chr1:28497343-28499801:+MESOMG.132EER1.6867e-04-0.4038image
ENSG00000204138.11,PHACTR4OVABT.263EAG3.5679e-030.1700image
chr1:28414433-28415216:+OVCisplatinEER4.5455e-03-0.4294image
chr1:28497343-28499801:+OVABT.263EER1.0503e-030.1908image
ENSG00000204138.11,PHACTR4PAADDocetaxelEAG5.9582e-03-0.2095image
chr1:28497343-28499801:+PAADDocetaxelEER5.9582e-03-0.2095image
chr1:28497343-28499801:+PCPGBI.2536EER2.8301e-040.2690image
ENSG00000204138.11,PHACTR4PCPGBI.2536EAG2.8301e-040.2690image
ENSG00000204138.11,PHACTR4PRADAZD.2281EAG8.8754e-04-0.1486image
chr1:28497343-28499801:+PRADBMS.536924EER2.1120e-03-0.1377image
ENSG00000204138.11,PHACTR4READAZD7762EAG1.1215e-03-0.3293image
chr1:28497343-28499801:+READAZD7762EER1.1482e-03-0.3286image
chr1:28497343-28499801:+SARCAG.014699EER2.0741e-030.1912image
ENSG00000204138.11,PHACTR4SARCAG.014699EAG1.8805e-030.1930image
chr1:28497343-28499801:+SKCMAZD6244EER4.4587e-09-0.2661image
ENSG00000204138.11,PHACTR4SKCMAZD6244EAG1.8532e-09-0.2724image
chr1:28450674-28452353:+STADBryostatin.1EER1.0728e-020.5325image
chr1:28497343-28499801:+STADDoxorubicinEER9.3047e-050.2015image
chr1:28414433-28415216:+STADGefitinibEER4.0711e-02-0.1903image
ENSG00000204138.11,PHACTR4STADFH535EAG1.2095e-050.2250image
chr1:28483186-28484282:+STADGSK269962AEER2.9740e-02-0.3972image
chr1:28471908-28473269:+STADAUY922EER2.8955e-02-0.3091image
chr1:28448988-28449781:+STADEHT.1864EER1.7985e-02-0.3513image
chr1:28407845-28408519:+STADGNF.2EER1.5820e-030.3707image
ENSG00000204138.11,PHACTR4TGCTGefitinibEAG5.5366e-04-0.2743image
chr1:28497343-28499801:+TGCTGefitinibEER5.5366e-04-0.2743image
chr1:28497343-28499801:+THCAIPA.3EER5.7567e-080.2390image
ENSG00000204138.11,PHACTR4THCAIPA.3EAG3.4011e-080.2430image
ENSG00000204138.11,PHACTR4THYMDasatinibEAG3.4727e-05-0.3790image
chr1:28497343-28499801:+THYMAZD6244EER1.8036e-08-0.4993image
ENSG00000204138.11,PHACTR4UCECGDC.0449EAG8.9438e-09-0.4165image
chr1:28497343-28499801:+UCECLenalidomideEER1.5810e-06-0.3536image
chr1:28497343-28499801:+UCSBortezomibEER4.0742e-04-0.4564image
ENSG00000204138.11,PHACTR4UCSBortezomibEAG4.0890e-04-0.4563image
ENSG00000204138.11,PHACTR4UVMBexaroteneEAG1.5552e-04-0.4154image
chr1:28497343-28499801:+UVMBexaroteneEER1.5552e-04-0.4154image


Top

check button EAGs targeted by drugs from DrugBank database.
* EAG: EER-associated genes.
EERENSTUniprotIDDrugBankIDDrugDrugType